Journal of Clinical Oncology
Articles in this Issue
Phase 1/2 study of zilovertamab vedotin in pediatric and young adult hematologic malignancies or solid tumors (LIGHTBEAM-U01A).
TPS10075 Background: ROR1 is an oncofetal protein expressed in various blood and solid cancers. Zilovertamab vedotin (ZV) is an antibody-drug conjugate co...
Final results of a phase 1 study of EP0031, a next generation selective RET inhibitor (SRI) in patients with SRI naïve or pretreated advanced RET-altered tumors.
8598 Background: EP0031 (A400/KL590586), a first in class next gen selective RET inhibitor (SRI) with FDA Fast Track Desig...
Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on immunotherapy efficacy in advanced hepatocellular carcinoma.
e16234 Background: Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are common medications used for managing hypert...
HER2DX prognostic value in older patients with HER2-positive early breast cancer: A correlative analysis from the RESPECT phase III trial.
532 Background: HER2DX, the first multigene assay specifically designed for HER2+ breast cancer, has demonstrated potential to guide treatment decisions....
Treatment discontinuation in desmoid tumors: Factors associated with better outcomes after sorafenib discontinuation.
11562 Background: Sorafenib has shown effectiveness in managing desmoid tumors. However, the optimal duration of systemic therapy and the outcomes followi...
Molecular profiling of neoadjuvant immunochemotherapy and identification of residual cancer cells in pCR NSCLC: A single-cell analysis of CTONG 1804 clinical trial.
8025 Background: Previously, we reported the clinical findings of stage-one enrollment from a phase II trial of neoadjuvant immunochemotherapy (IO) in unt...
Social determinants of health (SDOH) and late mortality among survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).
10021 Background: Neighborhood-level SDOH may increase disparities in adverse cancer-related outcomes. The US CDC-constructed Social Vulnerability Index (...
The role of healthcare system distrust in shaping patients’ attitudes and beliefs of artificial intelligence (AI) use in oncology.
1574 Background: AI offers significant potential to improve cancer care, yet little is known about patients’ attitudes and beliefs around its use and whic...
A randomized phase 2 study of the efficacy and safety of stereotactic body radiation therapy (SBRT) in patients with metastatic urothelial carcinoma and oligoprogression on maintenance therapy with avelumab (VOLGA 2).
TPS4620 Background: For metastatic urothelial cancer (mUC) with multiple metastases, the standard treatment involves plati...
Prognostic impact of brain metastases on survival rates in patients with metastatic testicular cancer: A comprehensive registry-based analysis.
5023 Background: Testicular cancer (TC) is a rare malignancy that accounts for less than 1% of all cancers. Advances in the treatment paradigm have improv...
Evaluating the use of educational videos in a medical oncology sarcoma clinic to improve patient knowledge and satisfaction.
TPS9047 Background: The first clinic visit is a pivotal step in the journey of a cancer patient (pt), often accompanied by anxiety due to future uncertain...
Late effects in high-risk neuroblastoma survivors who received MIBG therapy.
10034 Background: Meta-iodobenzylguanidine radiolabeled with iodine-131 ( 131 I-MIBG) is used to treat high-risk neuroblastoma (HR...
SPYK04, a novel RAF-MEK molecular glue: Dose escalation (DE) in first-in-human study for MAPK pathway-altered solid tumors.
3100 Background: SPYK04 is a novel MEK1/2 inhibitor designed to enhance RAF-MEK binding and potentially inhibit feedback activation of MEK1/2. This approa...
Evaluation of immune checkpoint inhibitors and concurrent radiation therapy for the treatment of extramedullary multiple myeloma.
e19549 Background: The prognosis of patients with extramedullary myeloma (EMM) is poor, and the median overall survival of patients who experience an extr...
Temporal trends of suicide among cancer patients: A SEER database analysis from 2000 to 2021.
12115 Background: Cancer is a known cause of morbidity and mortality, with over 2 million new diagnoses and 600,000 deaths projected in 2024. Some of the...
Outcomes in liver transplant recipients with and without diabetes: A propensity-matched analysis using the TriNetX database.
e23094 Background: Diabetes mellitus (DM) is a common comorbidity among liver transplant recipients and has been associate...
Sapanisertib and serabelisib (PIKTOR) with paclitaxel and a diet substudy in patients with advanced/recurrent endometrial cancer (GOG-3111).
TPS5633 Background: Patients with advanced/recurrent endometrial cancer have limited 2L+ treatment options. The PI3K/mTOR pathway regulates glucose homeos...
Interrogating the interleukin-6 (IL-6)/IL-23/T-helper (Th)17 axis in immunotherapy toxicity: Mechanistic insights and therapeutic implications.
12134 Background: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but grade ≥ 3 immune-related adverse events (irAEs) affect 60% of p...
Epidemiologic patterns and mortality outcomes in young lung cancer non-smokers: A National Inpatient Sample analysis (2016–2021).
11142 Background: While the incidence and mortality of smoking-related lung cancer have declined, cases among individuals who have never smoked (LCINS) ar...
Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL: Results in SEQUOIA arm D.
7009 Background: Zanu monotherapy demonstrated superior progression-free survival (PFS) compared with bendamustine + rituximab in patients (pts) without d...
Knowledge and practice of geriatric oncology among cancer care providers in Africa: A CROSS-sectional survey.
e13848 Background: Africa is witnessing an increase in its older population and in cancer incidence, but little is known about the regional status of geri...
Exploratory analyses of homologous recombination repair alterations (HRRm) by gene subgroup and potential associations with efficacy in the HRR-deficient population from TALAPRO-2.
5019 Background: In TALAPRO-2, talazoparib (TALA) + enzalutamide (ENZA) significantly improved radiographic progression-free survival (rPFS) and overall s...
Clinical outcomes for Medicaid recipients with early-onset breast cancer: An analysis of the National Inpatient Sample.
11180 Background: Despite recent global decreases in overall cancer incidence, the incidence of early-onset breast cancer (EOBC) is steadily increasing gl...
Efficacy and safety of first-line prolgolimab and nurulimab versus nivolumab and ipilimumab in advanced or metastatic melanoma: Indirect treatment comparison.
e21517 Background: Nivolumab and ipilimumab (NIVO+IPI) is considered one of the key immunotherapy combinations for patients with metastatic melanoma, as e...
Improving clinical trial interpretability and efficiency: A Bayesian re-analysis of individual patient outcomes from 230 phase III oncology trials.
11018 Background: The conventional interpretation of superiority oncology trials relies on statistical significance defined by P v...